Smac agonists sensitize for Apo2L/TRAIL-or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo

Nature Medicine

Volumn 8, Issue 8, 2002, Pages 808-815

  Fulda, Simone ^a   Wick, Wolfgang ^b   Weller, Michael ^b   Debatin, Klaus Michael ^a,c  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; CASPASE; CYTOTOXIC AGENT; PROTEIN BCL 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TISSUE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BRAIN; CARRIER PROTEINS; CASPASES; ENZYME INHIBITORS; FLOW CYTOMETRY; GLIOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; NEOPLASM TRANSPLANTATION; PEPTIDES; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; REMISSION INDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

ANIMALIA; MUS MUSCULUS;

EID: 0036341291     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm735     Document Type: Article

References (45)

1. Cancer epidemiology in the last century and the next decade
2. Cancer genetics
3. Apoptosis in cancer
4. From bench to clinic with apoptosis-based therapeutic agents
5. The biochemistry of apoptosis
6. Cellular stress response and apoptosis in cancer therapy
7. Apoptosis and the response to anticancer therapy
8. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
9. Cell type specific activation of death receptor and mitochondrial pathways in drug-induced apoptosis
10. Sensitization for death receptor- or drug-induced apoptosis by reexpression of caspase-8 through demethylation or gene transfer
11. Death receptors: Signaling and modulation
12. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems
13. Caspases: Enemies within
14. Two CD95 (APO-1/Fas) signaling pathways
15. Mitochondrial control of cell death
16. Cross-talk in cell death signaling
17. The Bcl-2 protein family
18. Cell death inhibition: Keeping caspases in check
19. IAP family proteins-suppressors of apoptosis
20. Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma
21. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
22. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins
23. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis
24. Structural and biochemical basis of apoptotic activation by Smac/DI-ABLO
25. Apoptotic pathways: Paper wraps stone blunts scissors
26. Overexpression of Bcl-2 inhibits TRAIL-induced apoptosis
27. Structural basis of IAP recognition by Smac/DIABLO
28. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in a thymic mice in the absence of neurotoxicity
29. MHC haplotype-dependent regulation of MOG-induced EAE in rats
30. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
31. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4
32. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
33. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
34. Safety and anti-tumor activity of recombinant soluble Apo 2 ligand
35. The potential of TRAIL for cancer chemotherapy
36. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
37. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO
38. Role of BAX in the apoptotic response to anticancer agents
39. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
40. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria
41. Brain tumors
42. TRAIL/Apo-2-Ligand induced apoptosis in T-cells
43. Improved culture methods to expand Schwann cells with altered growth behaviour from CMT1A patients
44. Cell-penetrating peptides
45. Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway